A novel macrolide-Del-1 axis to regenerate bone in old age.
Age
Immunology
Small molecule
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
16 Feb 2024
16 Feb 2024
Historique:
received:
15
09
2023
revised:
24
10
2023
accepted:
02
01
2024
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
Aging is associated with increased susceptibility to chronic inflammatory bone loss disorders, such as periodontitis, in large part due to the impaired regenerative potential of aging tissues. DEL-1 exerts osteogenic activity and promotes bone regeneration. However, DEL-1 expression declines with age. Here we show that systemically administered macrolide antibiotics and a non-antibiotic erythromycin derivative, EM-523, restore DEL-1 expression in 18-month-old ("aged") mice while promoting regeneration of bone lost due to naturally occurring age-related periodontitis. These compounds failed to induce bone regeneration in age-matched DEL-1-deficient mice. Consequently, these drugs promoted DEL-1-dependent functions, including alkaline phosphatase activity and osteogenic gene expression in the periodontal tissue while inhibiting osteoclastogenesis, leading to net bone growth. Macrolide-treated aged mice exhibited increased skeletal bone mass, suggesting that this treatment may be pertinent to systemic bone loss disorders. In conclusion, we identified a macrolide-DEL-1 axis that can regenerate bone lost due to aging-related disease.
Identifiants
pubmed: 38261928
doi: 10.1016/j.isci.2024.108798
pii: S2589-0042(24)00019-1
pmc: PMC10797555
doi:
Types de publication
Journal Article
Langues
eng
Pagination
108798Informations de copyright
© 2024 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.